This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New Research To Be Presented At IDWeek 2012

SAN DIEGO, Oct. 15, 2012 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) today announced that new research findings for Clostridium difficile infection (CDI) and DIFICID® (fidaxomicin) tablets will be featured in presentations at IDWeek 2012 occurring October 17-21 in San Diego, CA.


Oral Presentations
  • 692 – "Risk Factors for Recurrent Clostridium difficile Infection (CDI) Hospitalization among Hospitalized Patients with an Initial CDI Episode" – Friday, October 19 from 11:30 a.m. Pacific Time in SDCC 29 ABCD
  • 693 – "Length of Stay and Hospital Costs in Patients with Hospital-Origin Clostridium difficile-Associated Diarrhea" – Friday, October 19 from 11:45 a.m. Pacific Time in SDCC 29 ABCD

Poster Presentations
  • 316 – "Development and Validation of a Recurrent Clostridium difficile (CDI) Risk Prediction Model"  – Thursday, October 18 from 12:30 PM to 2:00 p.m. Pacific Time in : Room: SDCC Poster Hall F-H
  • 824 – "Comparative Microbiology of Transcription Inhibitors Fidaxomicin and the Rifamycins in Clostridium difficile" – Friday, October 19 from 12:30 PM to 2:00 p.m. Pacific Time in : Room: SDCC Poster Hall F-H

About  Clostridium difficile-associated Diarrhea (CDAD)

Clostridium difficile infection (CDI) is a serious illness resulting from infection of the inner lining of the colon by  C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death.   Clostridium difficile-associated diarrhea is the most common symptom of CDI.  In recent years,  C. difficile has surpassed methicillin-resistant  Staphylococcus aureus (MRSA) as the leading cause of healthcare-acquired infections in community hospitals.  Patients typically develop CDAD from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, possibly allowing  C. difficile bacteria to flourish.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs